

## PRIOR AUTHORIZATION POLICY

- POLICY:** Topical Retinoids – Tazarotene Products Prior Authorization Policy
- Arazlo™ (tazarotene 0.045% lotion – Bausch Health)
  - Fabior® (tazarotene 0.1% foam – Mayne Pharma)
  - Tazorac® (tazarotene 0.05% cream, 0.05% gel, 0.1% cream, and 0.1% gel – Allergan, generic to 0.1% cream only)

**REVIEW DATE:** 07/14/2021

---

### OVERVIEW

Tazorac gel is indicated for the following uses:<sup>1</sup>

- **Plaque psoriasis**, in patients with up to 20% body surface area involvement (0.05% and 0.1% strengths).
- **Facial acne vulgaris**, in patients with mild to moderate severity (0.1% strength only).

Tazorac cream is indicated for the following uses:<sup>2</sup>

- **Plaque psoriasis** (0.05% and 0.1% strengths).
- **Acne vulgaris** (0.1% strength only).

Both Arazlo lotion and Fabior foam are indicated for the topical treatment of **acne vulgaris**.<sup>3,4</sup>

In addition to acne vulgaris and plaque psoriasis, topical tazarotene products have been used to treat other medical skin conditions, such as basal cell carcinoma and congenital ichthyoses.<sup>5</sup> Topical tazarotene products have also been used to treat cosmetic skin conditions such as wrinkles, premature aging, and treatment of photo-aged or photo-damaged skin.

### POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of topical tazarotene products. All approvals are provided for the duration noted below.

**Automation:** None.

### RECOMMENDED AUTHORIZATION CRITERIA

Coverage of topical tazarotene products is recommended in those who meet the following criteria:

#### FDA-Approved Indications

1. **Acne Vulgaris.** Approve for 3 years.
  2. **Plaque Psoriasis (Psoriasis Vulgaris).** Approve for 3 years.
-

## Other Uses with Supportive Evidence

### 3. Treatment of Other Non-Cosmetic Conditions. Approve for 1 year.

Note: Examples of other non-cosmetic conditions include: psoriasis of fingernails or toenails, oral lichen planus, congenital ichthyoses (X-linked recessive ichthyosis, non-erythrodermic autosomal recessive lamellar ichthyosis, autosomal dominant ichthyosis vulgaris), basal cell carcinoma, mycosis fungoides, cutaneous T-cell lymphoma, keratosis pilaris (atrophicans), actinic keratoses, skin neoplasms, warts, dermatitis/eczema, folliculitis, acne rosacea, cystic acne, comedonal acne.

## CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of topical tazarotene products is not recommended in the following situations:

### 1. Cosmetic Conditions. Cosmetic use is not recommended for coverage as this indication is excluded from coverage in a typical pharmacy benefit.

Note: Examples of cosmetic conditions include: alopecia, hyperpigmentation, liver spots, melasma/cholasma, seborrheic keratosis, stretch marks, scarring, wrinkles, premature aging, photo-aged or photo-damaged skin, mottled hyper- and hypopigmentation, benign facial lentiginos, roughness, telangiectasia, skin laxity, keratinocytic atypia, melanocytic atypia, dermal elastosis.

### 2. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

## REFERENCES

1. Tazorac topical gel 0.05%, 0.1% [prescribing information]. Irvine, CA: Allergan; April 2018.
2. Tazorac cream 0.05%, 0.1% [prescribing information]. Irvine, CA: Allergan; July 2017.
3. Arazlo™ lotion [prescribing information]. Bridgewater, NJ: Bausch Health US; December 2019.
4. Fabior foam 0.1% [prescribing information]. Greenville, NC: Mayne Pharma; November 2016.
5. DRUGDEX® System. Thomson Reuters (Healthcare) Inc. Available at: <http://www.micromedexsolutions.com/home/dispatch>. Accessed on July 8, 2021. Search term: tazarotene.

## HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	<b>Acne Vulgaris.</b> Removed the requirement that patient has had a trial with at least one other topical retinoid product. <b>Non-Cosmetic Conditions Not Listed Above:</b> The list of examples of was removed from the criteria and changed to a note. <b>Cosmetic Conditions:</b> The list of examples of examples was removed from the criteria and changed to a note.	07/01/2020
Annual Revision	No criteria changes.	07/14/2021